Cargando…

Randomized Clinical Trial of Quick-Release Bromocriptine Among Patients With Type 2 Diabetes on Overall Safety and Cardiovascular Outcomes

OBJECTIVE: Quick-release bromocriptine (bromocriptine-QR), a D2 dopamine receptor agonist, is indicated as a treatment for type 2 diabetes. The Cycloset Safety Trial, a 52-week, randomized, double-blind, multicenter trial, evaluated the overall safety and cardiovascular safety of this novel therapy...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gaziano, J. Michael, Cincotta, Anthony H., O'Connor, Christopher M., Ezrokhi, Michael, Rutty, Dean, Ma, Z.J., Scranton, Richard E.
Formato:	Texto
Lenguaje:	English
Publicado:	American Diabetes Association 2010
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2890350/ https://www.ncbi.nlm.nih.gov/pubmed/20332352 http://dx.doi.org/10.2337/dc09-2009

Ejemplares similares

Timed Bromocriptine-QR Therapy Reduces Progression of Cardiovascular Disease and Dysglycemia in Subjects with Well-Controlled Type 2 Diabetes Mellitus
por: Chamarthi, Bindu, et al.
Publicado: (2015)

Effect of Bromocriptine-QR (a Quick-Release Formulation of Bromocriptine Mesylate) on Major Adverse Cardiovascular Events in Type 2 Diabetes Subjects
por: Gaziano, J. Michael, et al.
Publicado: (2012)

A randomized, double-blind, placebo-controlled trial to assess safety and tolerability during treatment of type 2 diabetes with usual diabetes therapy and either Cycloset™ or placebo
por: Scranton, Richard E, et al.
Publicado: (2007)

Circadian‐timed quick‐release bromocriptine lowers elevated resting heart rate in patients with type 2 diabetes mellitus
por: Chamarthi, Bindu, et al.
Publicado: (2019)

Time-of-Day-Dependent Effects of Bromocriptine to Ameliorate Vascular Pathology and Metabolic Syndrome in SHR Rats Held on High Fat Diet
por: Ezrokhi, Michael, et al.
Publicado: (2021)

Effect of Bromocriptine‐QR (a Quick‐Release Formulation of Bromocriptine Mesylate) on Major Adverse Cardiovascular Events in Type 2 Diabetes Subjects
Publicado: (2015)

Bromocriptine-QR Therapy Reduces Sympathetic Tone and Ameliorates a Pro-Oxidative/Pro-Inflammatory Phenotype in Peripheral Blood Mononuclear Cells and Plasma of Type 2 Diabetes Subjects
por: Cincotta, Anthony H., et al.
Publicado: (2022)

Brain Dopamine–Clock Interactions Regulate Cardiometabolic Physiology: Mechanisms of the Observed Cardioprotective Effects of Circadian-Timed Bromocriptine-QR Therapy in Type 2 Diabetes Subjects
por: Cincotta, Anthony H.
Publicado: (2023)

Neuroendocrine and metabolic components of dopamine agonist amelioration of metabolic syndrome in SHR rats
por: Ezrokhi, Michael, et al.
Publicado: (2014)

Erratum: Neuroendocrine and metabolic components of dopamine agonist amelioration of metabolic syndrome in SHR rats
por: Ezrokhi, Michael, et al.
Publicado: (2015)

Bromocriptine, a clinical and pharmacological review /
por: Thorner, Michael O.
Publicado: (1980)

Evaluation of the efficacy and safety of bromocriptine QR in type 2 diabetes
por: Ramteke, Karuna Balwant, et al.
Publicado: (2011)

Nerve growth factor and bromocriptine: a sequential therapy for human bromocriptine-resistant prolactinomas.
por: Missale, C., et al.
Publicado: (1995)

Prediction of response to bromocriptine in acromegaly.
por: Atkinson, A. B., et al.
Publicado: (1978)

Repurposing of Bromocriptine for Cancer Therapy
por: Seo, Ean-Jeong, et al.
Publicado: (2018)

Central Hyperthermia Treated with Bromocriptine
por: Natteru, P., et al.
Publicado: (2017)

Effect of bromocriptine on cardiovascular complications associated with metabolic syndrome in fructose fed rats
por: Nade, Vandana S., et al.
Publicado: (2012)

Bromocriptine and insulin sensitivity in lean and obese subjects
por: Bahler, L, et al.
Publicado: (2016)

Bromocriptine in type 2 diabetes mellitus
por: Shivaprasad, C., et al.
Publicado: (2011)

Experimental dopaminergic neuron lesion at the area of the biological clock pacemaker, suprachiasmatic nuclei (SCN) induces metabolic syndrome in rats
por: Luo, Shuqin, et al.
Publicado: (2021)

Cardiovascular and Renal Effects of Bromocriptine in Diabetic Patients with Stage 4 Chronic Kidney Disease
por: Mejía-Rodríguez, Oliva, et al.
Publicado: (2013)

Bromocriptine as a new therapeutic agent for peripartum cardiomyopathy
por: Chopra, Sandeep, et al.
Publicado: (2012)

Bromocriptine monotherapy overcomes prostate cancer chemoresistance in preclinical models
por: Bai, Lijuan, et al.
Publicado: (2023)

Management of pituitary tumour apoplexy with bromocriptine in pregnancy
por: Janssen, Nina M, et al.
Publicado: (2012)

Bromocriptine Does Not Alter Speed–Accuracy Tradeoff
por: Winkel, Jasper, et al.
Publicado: (2012)

Repositioning of bromocriptine for treatment of acute myeloid leukemia
por: Lara-Castillo, María Carmen, et al.
Publicado: (2016)

Effects of tolcapone and bromocriptine on cognitive stability and flexibility
por: Cameron, Ian G. M., et al.
Publicado: (2018)

Bromocriptine Use in Peripartum Cardiomyopathy: Review of Cases
por: Simon, Rebecca, et al.
Publicado: (2018)

Circadian peak dopaminergic activity response at the biological clock pacemaker (suprachiasmatic nucleus) area mediates the metabolic responsiveness to a high‐fat diet
por: Luo, S., et al.
Publicado: (2018)

Bromocriptine for the treatment of peripartum cardiomyopathy: a multicentre randomized study
por: Hilfiker-Kleiner, Denise, et al.
Publicado: (2017)

Bromocriptine treatment in patients with peripartum cardiomyopathy and right ventricular dysfunction
por: Haghikia, Arash, et al.
Publicado: (2018)

Dopaminergic Challenge With Bromocriptine in Patients With Severe Brain Injury
por: Celik, JB, et al.
Publicado: (2015)

Efficacy of bromocriptine on glycemic and metabolic control of prediabetic patients
por: Khalilzade, Saied Hossein, et al.
Publicado: (2015)

Bromocriptine inhibits proliferation in the endometrium from women with adenomyosis
por: Tang, Yiqun, et al.
Publicado: (2023)

Dual pancreatic adrenergic and dopaminergic signaling as a therapeutic target of bromocriptine
por: Aslanoglou, Despoina, et al.
Publicado: (2022)

Bromocriptine Therapy for the Treatment of Invasive Prolactinoma: The Single Institute Experience
por: Cho, Kyung Rae, et al.
Publicado: (2013)

AB086. The effect of Xuanju compound capsule combined with bromocriptine
por: Bian, Jun, et al.
Publicado: (2016)

Role of bromocriptine in multi-spectral manifestations of traumatic brain injury
por: Munakomi, Sunil, et al.
Publicado: (2017)

A Systematic Review of the Utility of Bromocriptine in Acute Peripartum Cardiomyopathy
por: Badianyama, Marheb, et al.
Publicado: (2021)

Comparison of bromocriptine and hydroxyethyl starch in the prevention of ovarian hyperstimulation syndrome
por: Zhang, Qiaoli, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_n3sgn9g1ftq88coi27uggg619k